AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts – AZN Stock Eyes Breakout After Q3 Earnings Beat
Core earnings per share increased 17% to $2.79, beating consensus estimates of $2.59. The company announced a restructuring…